Dr. Hu-Lieskovan’s laboratory uses cutting-edge technologies to investigate mechanisms of resistance to immunotherapy, develop novel combination strategies to overcome resistance, improve efficacy, and monitor and prevent immunotherapy-induced toxicities. Her team conducts clinical trials to bring the discovery from her laboratory to the clinic and to improve the effectiveness and tolerability of immunotherapy, with the ultimate goal of bringing the survival benefit of immunotherapy to every patient.